Erratum: Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis (Haematologica (2021) 106:4 (1182-1187) DOI: 10.3324/haematol.2020.253450)

  • Fredrik Schjesvold
  • , Paul G. Richardson
  • , Thierry Facon
  • , Adrián Alegre
  • , Andrew Spencer
  • , Artur Jurczyszyn
  • , Kazutaka Sunami
  • , Laurent Frenzel
  • , Chang Ki Min
  • , Sophie Guillonneau
  • , Peggy L. Lin
  • , Solenn Le-Guennec
  • , Frank Campana
  • , Helgi van de Velde
  • , Samira Bensfia
  • , Sara Bringhen

Research output: Contribution to journalComment/debate

3 Scopus citations

Abstract

In the article by Schjesvold et al., entitled “Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis”, which appeared in the April 2021 issue of Haematologica (volume 106, pages 1182-1187), the values entered for “Refractory status” at the bottom of Table 1 were incorrect. The authors have prepared a new, corrected version of Table 1, which is reported here. The authors apologize to the Editor and readers for their mistake. They want to underscore that the results and conclusions of the paper are unaffected by the error.

Original languageEnglish
Pages (from-to)774-775
Number of pages2
JournalHaematologica
Volume107
Issue number3
DOIs
StatePublished - Mar 2022

Bibliographical note

Publisher Copyright:
© 2022 Ferrata Storti Foundation.

Fingerprint

Dive into the research topics of 'Erratum: Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis (Haematologica (2021) 106:4 (1182-1187) DOI: 10.3324/haematol.2020.253450)'. Together they form a unique fingerprint.

Cite this